In an escalating legal development, The Federal Trade Commission (FTC) has recently initiated a lawsuit against two entities: the U.S. Anesthesia Partners, Inc. (USAP) and a private equity company identified as Welsh, Carson, Anderson & Stowe XI, L.P. along with its affiliated entities (collectively referred to as Welsh Carson). The crux of the lawsuit is the allegation that the defendants have violated provisions of both the Clayton Act and the FTC Act. These violations are purportedly a result of their participation in an anticompetitive scheme aiming to monopolize the anesthesiology market in Texas.
The FTC antitrust action against USAP and Welsh Carson highlights important considerations for private equity firms and healthcare providers. It echoes earlier enforcement actions as it further pursues monopolistic practices, specifically in healthcare services.
This case underscores the increasing scrutiny on private entities in the healthcare industry for their role in potential monopolistic practice, particularly those that could stifle competition. It follows prior pursuits of the FTC and Department of Justice against hospital mergers seen to impact negatively on market competition.
For the legal professionals in healthcare arena, this lawsuit illustrates the importance of maintaining vigilance over regulatory concerns, especially with regard to potentially monopolistic strategies. Reviewing arrangements for potential antitrust issues can help to prevent possible future enforcement instances.
It will be paramount for healthcare professionals, and indeed professionals in any sector, to acquaint themselves with the details of this case and assimilate the implications it has on their practices. The outcome of this lawsuit could precipitate a momentum in the government’s future dealings with alleged anticompetitive practices.
The full lawsuit text along with further developments in this case can be accessed here.